On March 3, the Department of Molecular and Human Genetics and the NCI- designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine hosted their first joint U.S.-Japan Clinical Cancer Genomics and Personalized Medicine Symposium in Tokyo, Japan, a meeting on state-of-the-art cancer genetics and genomics.
“This is an exciting time, as the Japanese government is leading implementation and support for cancer genetic testing in its healthcare system,” said Dr. Brendan Lee, chair and the Robert and Janice McNair Endowed Chair and professor of molecular and human genetics at Baylor. “In 2015, there were approximately 981,000 cases of cancer affecting men and women. The advent of genetic testing may improve detection, diagnosis, choice of targeted therapies and monitoring.”
Speakers included leading genetics and cancer researchers, with presentations focused on the implementation of cancer genetic testing in Japan. Baylor was represented by Drs. Lee, Shashikant Kulkarni, David Wheeler, Matthew Ellis and Sharon Plon, all of whom presented to leading oncologists during the symposium.
The meeting was sponsored and hosted by Miraca Holdings, the joint venture partner in Baylor Genetics, Baylor’s genetic diagnostic laboratory.
As a result of the symposium, future plans include following up with collaborations among Baylor research faculty and also engaging Baylor Genetics to consider developing a diagnostic testing roadmap for use in Japan.